HMA - Heads of Medicines Agencies
  • RSS
  • Sitemap
  • Contact
  • About HMA
  • Human Medicines
  • Veterinary Medicines
  • You are here:
  • Home
  • >Human Medicines
  • >CMDh
  • >Procedural Guidance
  • >Variation
  • >Art 5 recommendations
  • CMDh
    • About CMDh
    • Statistics
    • Agendas and Minutes
    • Press Releases
    • BREXIT
    • Procedural Guidance
      • General Info
      • Application for MA
      • eSubmissions
      • Generics
      • ApplicantĀ“s Responses
      • Renewal
      • Consultation with target patient groups
      • Variation
        • Art 5 recommendations
      • USR
      • Art 61.3 Procedure
      • Post Referral Phase
    • CMDh-Referrals
    • Product Information
    • Advice from CMDh
    • Templates
    • CMD Working Parties / Working Groups
    • Paediatric Regulation
    • Pharmacovigilance
    • Falsified Medicines
    • IGDRP
    • Questions & Answers
    • Contact Points
    • What's new history
  • MRI Product Index
  • Pharmacovigilance
  • Publications and reports
  • National Contacts

Art.5 on Unforeseen Variations

  • Timetables 2017 for requests to CMDh for a recommendation on classification of an unforseen variation - Article 5 (September 2016)
  • CMDh Recommendation for classification of unforeseen variations according to Article 5 of Commission Regulation (EC) 1234/2008 (March 2017)
  • CMDv Recommendations for Classification of Unforeseen Variations according to Article 5 of Commission Regulation (EC) 1234/2008

Templates

  •  Template of the Article 5
  • Useful Links
  • Privacy Policy
  • Credits & Disclaimer
  • Contact
© Heads of Medicines Agencies - http://www.hma.eu/293.html